[HTML][HTML] Breakthroughs in hepatitis C research: from discovery to cure
MP Manns, B Maasoumy - Nature reviews Gastroenterology & …, 2022 - nature.com
In the 1970s, an unknown virus was suspected for documented cases of transfusion-
associated hepatitis, a phenomenon called non-A, non-B hepatitis. In 1989, the infectious …
associated hepatitis, a phenomenon called non-A, non-B hepatitis. In 1989, the infectious …
[HTML][HTML] Hepatocellular carcinoma: old friends and new tricks
E Kim, P Viatour - Experimental & molecular medicine, 2020 - nature.com
Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer and a leading
cause of cancer-related deaths worldwide. Ninety percent of HCC cases arise from cirrhosis …
cause of cancer-related deaths worldwide. Ninety percent of HCC cases arise from cirrhosis …
[PDF][PDF] Global distribution and prevalence of hepatitis C virus genotypes
JP Messina, I Humphreys, A Flaxman, A Brown… - …, 2015 - Wiley Online Library
Hepatitis C virus (HCV) exhibits high genetic diversity, characterized by regional variations
in genotype prevalence. This poses a challenge to the improved development of vaccines …
in genotype prevalence. This poses a challenge to the improved development of vaccines …
[HTML][HTML] EASL recommendations on treatment of hepatitis C 2015
European Association For The Study Of The Liver - Journal of hepatology, 2015 - Elsevier
Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease
worldwide [1]. The long-term impact of HCV infection is highly variable, ranging from minimal …
worldwide [1]. The long-term impact of HCV infection is highly variable, ranging from minimal …
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the …
Background Chronic hepatitis C virus (HCV) infection in patients with stage 4–5 chronic
kidney disease increases the risk of death and renal graft failure, yet patients with hepatitis C …
kidney disease increases the risk of death and renal graft failure, yet patients with hepatitis C …
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection
Background In phase 2 studies, treatment with the all-oral combination of the nucleotide
polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of …
polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of …
[PDF][PDF] Health care for women subjected to intimate partner violence or sexual violence: A clinical handbook
World Health Organization - 2014 - apps.who.int
Gesundheitliche Versorgung von Frauen, die Gewalt in der Paarbeziehung oder sexuelle Gewalt
erfahren Page 1 Gesundheitliche Versorgung von Frauen, die Gewalt in der Paarbeziehung oder …
erfahren Page 1 Gesundheitliche Versorgung von Frauen, die Gewalt in der Paarbeziehung oder …
[PDF][PDF] All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study
Treatment options for patients with hepatitis C virus (HCV) genotype 3 infection are limited,
with the currently approved all‐oral regimens requiring 24‐week treatment and the addition …
with the currently approved all‐oral regimens requiring 24‐week treatment and the addition …
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis
Background High rates of sustained virologic response were observed among patients with
hepatitis C virus (HCV) infection who received 12 weeks of treatment with the nucleotide …
hepatitis C virus (HCV) infection who received 12 weeks of treatment with the nucleotide …
Treatment of HCV infection by targeting microRNA
HLA Janssen, HW Reesink, EJ Lawitz… - … England Journal of …, 2013 - Mass Medical Soc
Background The stability and propagation of hepatitis C virus (HCV) is dependent on a
functional interaction between the HCV genome and liver-expressed microRNA-122 (miR …
functional interaction between the HCV genome and liver-expressed microRNA-122 (miR …